Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206556 · ClinicalTrials.gov registry record
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
A clinical trial, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Completed
- Registry status
- 97
- Enrollment target
NCT01206556 is a clinical trial that has completed, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 97 participants.
The verdict
NCT01206556 has completed, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
Study Summary
This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists. The immune response occurred after immunization and is what protects you/your child from HPV disease. You / your child received this vaccine as part of an earlier study (P1047). The vaccine is called Human Papillomavirus Vaccine (QHPV Vaccine, also known as GARDASIL®). The study will check to see if the protective effects (called "antibodies") produced by the vaccine have lasted, and for how long these effects will continue to last. You will not be given any medications or vaccines as part of this follow-up study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206556
The ClinicalTrials.gov registry entry for NCT01206556 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01206556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01206556 about?
NCT01206556 is a clinical study titled "IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody". This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists. The immune response occurred after immunization and is what protects you/your child from HPV disease. You / your child received this vaccine as part of a...
What is the current status of trial NCT01206556?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2010-05. Estimated completion is 2013-08.
Who is sponsoring clinical trial NCT01206556?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.